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This series of case reports describes 10 cases out of a total of 
~100 patients with COVID-19 admitted to a hospital in a small coastal 
town in the Western Cape region of South Africa (SA) from May  2020 
to June 2021 and treated by author GC. The nearest tertiary care 
facilities are 150 km away, so general physicians have to treat many 
problems that would normally be referred to specialised centres.
The study was approved by the Health Sciences Research Ethics 
Committee of the University of Cape Town (ref. no. 258/2021).
Case reports
Cases 1 and 2: Exercise after COVID-19 –  
a cautionary tale
These two cases illustrate the importance of medical review before 
exercising after COVID-19 infection.
Case 1 was a woman in her forties, who was admitted in July 2020 
with severe COVID-19 pneumonia. She had no known comorbidities 
and exercised regularly. There was a strong family history of 
diabetes, and during her admission she developed type 2 diabetes. 
She responded well to diet and oral agents and made an uneventful 
recovery. Six weeks later, on her own initiative, she decided to report 
back for a check-up prior to resuming running.
Findings on physical examination were unremarkable apart from 
the presence of sinus tachycardia of 100 bpm with frequent ectopic 
beats. Her blood pressure was 135/96 mmHg and her oxygen 
saturation (sats) 98%. An electrocardiogram (ECG) showed sinus 
rhythm with multiple ventricular ectopics (Fig. 1). On a multistage 
treadmill test, there were runs of ventricular tachycardia. Twenty-
four-hour Holter monitoring showed frequent ventricular ectopics, 
bigeminy, couplets and ventricular tachycardia (VT).
The diagnosis was almost certainly the result of a COVID-19 
myocarditis that resulted in scarring of the myocardium. A cardiac 
electrophysiological study identified a number of arrhythmogenic 
foci in the left ventricular outflow tract from which VT could be 
induced. These were ablated, and VT could no longer be induced. 
The patient is now able to exercise safely.
Case 2 was a fit woman in her thirties, with no previous medical 
history. She contracted mild COVID-19 pneumonia in July 2020, for 
which she was treated at home. Her course was uncomplicated and 
she recovered well. About one month later she started jogging again, 
and soon noticed that exertion brought on significant dyspnoea and 
pleuritic chest pain. She consulted her general practitioner, who did 
not find any clinical or ECG abnormalities and referred her to GC’s 
practice for an echocardiogram. This documented the presence of a 
small posterior pericardial effusion, probably related to COVID-19 
infection (Fig. 2).
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Fig. 1. Stress electrocardiogram of case 1 showing ventricular tachycardia.
Fig. 2. Echocardiogram showing thickened calcified posterior pericardium 
(arrow) with epicardial separation of 2 - 3 mm with diastolic flattening of 
the posterior pericardium.
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Cardiac complications of COVID-19 include myocardial injury, 
myocarditis, acute myocardial infarction, heart failure, dysrhythmias, 
pericarditis and venous thromboembolic events.[1] The prevalence 
is unclear, but acute myocarditis may account for up to 7% of 
deaths. It may present with a variety of symptoms including chest 
pain, dyspnoea, dysrhythmia, and acute left ventricular dysfunction 
with cardiogenic shock. Serum troponin values are generally 
abnormal. The ECG can demonstrate a range of findings including 
nonspecific ST-segment–T-wave abnormalities, T-wave inversion, 
PR-segment and ST-segment deviations (depression and elevation) 
and ventricular arrhythmias. The echocardiogram may be helpful 
in distinguishing pericarditis from acute myocardial infarction. 
The likely pathophysiology is a combination of the direct viral 
insult to cardiomyocytes, the immune response to virally infected 
myocardium, and drugs that prolong the QT interval.[2]
The later cardiac effects of COVID-19 are less well described, and 
milder cases of myocarditis may go unrecognised and pose potential 
risks. This possibility understandably leads to caution when advising 
a return to physical activity after infection. Without evidence from 
robust studies to inform practice, all current guidance to date is 
based on consensus or expert opinion.[3] The current consensus is 
to risk-stratify patients before recommending a return to physical 
activity. Patients with ongoing symptoms, who had severe COVID-
19 or with a history suggestive of cardiac involvement, need further 
clinical assessment that may include clinical examination, resting 
and effort ECGs, echocardiography and Holter monitoring, and 
cardiac magnetic imaging if indicated. In all other cases, after at least 
7 days free of symptoms, minimal exertion may be undertaken for 
2 weeks before increasing activity.[3] However, case 2 did not meet the 
criteria for detailed investigations, as a potentially fatal ventricular 
tachycardia was only detected on Holter monitoring. Perhaps a 
routine examination and ECG should be advised, as in our case 
multiple ventricular ectopics were detected that prompted further 
investigation.
Case 2 represents another cardiac complication of COVID-
19, namely pericarditis.[4] She typically presented with pleuritic 
chest pain. Pericarditis is usually mild, but may occasionally be 
associated with significant pericardial effusion and tamponade 
requiring therapeutic pericardiocentesis.[5] It can be present at 
the time of the initial diagnosis or occur later in the course of the 
disease. The appearance of an increased cardiac silhouette on the 
chest radiograph and typical features of ST elevation on the ECG 
may suggest pericarditis/pericardial effusion, which can usually be 
confirmed by transoesophageal echocardiography or a computed 
tomography (CT) scan.
These two cases illustrate that there is a need to consider a basic 
cardiac assessment before returning to exercise.
Case 3: Sudden severe dyspnoea after recovery from 
COVID-19 pneumonia
A man in his seventies was admitted in November 2020 with 
COVID-19 pneumonia and treated with low-molecular-weight 
heparin (LMWH), antibiotics and supplements. He was discharged 
5 days later, but within 72 hours was readmitted with a high fever and 
severe dyspnoea. At that stage, clinically he had severe pneumonia 
confirmed on a repeat high-resolution CT scan of the chest. Heparin 
was restarted and dexamethasone 6 mg daily added. The response 
was slow but satisfactory, and he was discharged 9 days later feeling 
quite well.
A few days later, while watching television at home, he had a 
sudden bout of coughing and slight haemoptysis, followed by severe 
dyspnoea. He only reported to casualty the following morning, and 
was found to be in severe respiratory distress with a sats of 80% on 
room air. Clinically a large left-sided tension pneumothorax was 
present (confirmed on CT scan of the chest, Fig. 3). An intercostal 
drain was inserted with dramatic symptomatic improvement. The 
further course was uncomplicated.
Pneumothorax and tension pneumothorax are uncommon but 
well-described complications of COVID-19 pneumonia. In a study 
of 3 368 patients with suspected COVID 19 pneumonia, 902 patients 
were nasopharyngeal swab-positive, and there were 6 cases (0.66%) 
of spontaneous pneumothorax.[6] Four of these cases were associated 
with mechanical ventilation and 2 occurred spontaneously.
Pneumothorax usually presents with increasing dyspnoea and may 
be confused with worsening pneumonia or thromboembolism. This 
is an important complication of COVID-19 to recognise, as it is easily 
remedied by insertion of an intercostal drain as in the case described.
Cases 4 and 5: Neurological complications
Case 4 was a healthy woman in her thirties who presented to the 
emergency room 140 minutes after experiencing right-sided paralysis 
and aphasia. She had had mild pre-eclampsia 7 years previously, 
with no sequelae or continuing hypertension. There was no history 
of cardiac pathology, atrial fibrillation, diabetes mellitus, thyroid 
disease, vascular/collagen disorders or dyslipidaemia. Her HIV status 
was negative and she was not on hormone replacement therapy. On 
physical examination she was apyrexial and in sinus rhythm with a 
sats of 98%. Her blood pressure was 128/75 mmHg and there was a 
dense right hemiplegia with expressive aphasia.
A diagnosis of acute ischaemic stroke was made, and in view 
of the presentation within 3 hours, after a CT scan of the brain 
confirmed no cerebral haemorrhage, she received thrombolysis with 
dramatic improvement of both the hemiplegia and aphasia. Extensive 
investigation showed no cause for her ischaemic stroke other than a 
positive COVID-19 test on admission. She had no other symptoms 
of COVID-19. She was anticoagulated with rivaroxaban and later 
low-dose aspirin. She made a very good recovery, with slight residual 
weakness in the right leg and arm.
Several neurological manifestations of COVID-19 are increasingly 
being recognised.[7] These include encephalopathy, encephalitis, 
Fig. 3. High-resolution computed tomography image demonstrating the 
pneumothorax.
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Guillain-Barré syndrome, anosmia, ageusia, transverse myelitis and 
acute cerebrovascular disease. Various studies report stroke in 
1.6 - 2.4% of patients hospitalised with COVID-19. Cryptogenic 
stroke (patients such as the case reported above, in whom no 
typical underlying cause of stroke is found) is being reported more 
frequently. The proposed mechanisms for these cerebrovascular 
events include a hypercoagulable state from systemic inflammation 
and cytokine storm, post-infectious immune-mediated responses, 
and viral-induced vasculitis potentially leading to thrombosis. 
Neurological problems caused directly or indirectly by the virus must 
be distinguished from nonspecific complications of severe disease 
(e.g. hypoxic encephalopathy and critical care neuropathy).
Case 5 was a woman in her thirties. In July 2020, she was 
hospitalised with severe bilateral pneumonia highly suggestive of 
COVID-19. Interestingly, the first three COVID-19 swabs were 
negative, and she only tested positive on the fourth occasion. 
Her treatment included dexamethasone 6 mg intravenously daily. 
Six days after admission she requested to be discharged, but was 
re-admitted the next day with severe dyspnoea at rest. Treatment was 
restarted and the dosage of dexamethasone increased from 6 mg to 
8 mg intravenously daily. She improved slowly, and 8 days later was 
discharged on high-dose prednisone. Shortly thereafter she became 
confused, aggressive and disorientated. This settled spontaneously, 
and she returned for follow-up 2 weeks later. At that stage, her 
mental state and the findings on detailed neurological examination 
were normal. A CT scan of the brain and routine blood tests were all 
unremarkable. She was reviewed by a psychiatrist and a diagnosis of 
probable steroid-induced psychosis was made.
The Association of British Neurologists launched a portal in April 
2020 to report neurological and neuropsychiatric complications of 
COVID-19.[8] Complete clinical datasets were available for 125 (82%) 
of 153 patients. Of these, 77 (62%) presented with a cerebrovascular 
event and 39 (31%) with altered mental status. The latter comprised 
9 patients (23%) with unspecified encephalopathy, 7 (18%) with 
encephalitis, and 23 (59%) with altered mental status fulfilling the 
clinical case definitions for psychiatric diagnoses. The relationship 
of the neuropsychiatric events to use of high-dose steroids was not 
reported. Although the psychiatrist reported that case 5 had steroid-
induced psychosis, it is possible that this was directly related to 
COVID-19 infection.
Case 6: Pulmonary sequelae of COVID-19 pneumonia
Case 6 was a woman in her seventies with the following comorbidi-
ties: atrial fibrillation due to longstanding hypertension, mild asthma, 
dyslipidaemia, hypothyroidism and depression. A chest radiograph 
performed in 2013 was normal. In September 2020 she presented 
with mild COVID-19 pneumonia and was admitted to hospital. 
A high-resolution CT chest scan showed multifocal ground-glass 
opacification in keeping with the diagnosis. She was treated according 
to the standard protocol, but was not given corticosteroids. She was 
anxious to go home and requested to be discharged. However, she 
was re-admitted 9 days later with increasing dyspnoea. The chest 
radiograph showed a bilateral coarse reticulonodular pattern with 
increased interstitial markings, and spirometry revealed a mild 
restrictive pattern.
Echocardiography documented a normal left ventricle with an 
ejection fraction of 63% and features of pulmonary hypertension. 
Two days later, the patient again requested to be discharged and 
was sent home on a short course of prednisone and a budesonide/
formoterol inhaler. A repeat high-resolution CT scan of the chest 
done as an outpatient showed good resolution of the ground-glass 
opacification and confirmed the presence of the reticulonodular 
pattern and interstitial changes noted on the chest radiograph. 
Shortly thereafter the patient left the area, and we were unable to do 
further investigations.
This case probably represents post-COVID-19 lung fibrosis, 
but a pre-existing interstitial lung disease could not be excluded. 
Post-COVID-19 fibrosis is one of the emerging complications of 
COVID-19 pneumonia. It is estimated to affect around one-third of 
COVID-19-infected hospitalised patients.[9] The predictors of lung 
fibrosis are advanced age, illness severity, length of intensive care 
unit (ICU) stay and mechanical ventilation, smoking and chronic 
alcoholism. Data regarding long-term clinical outcomes are not yet 
available, predictions for long-term outcome are speculative at best, 
and treatment with antifibrotic therapy with either pirfenidone or 
nintedanib is anecdotal.
Case 7: Renal infarction after COVID-19
Five weeks prior to presentation, a woman in her fifties had had 
mild COVID-19 with myalgia, fever, a non-productive cough and 
anosmia. She had been in contact with two couples on a trip, who 
all tested positive for COVID, but was not tested herself for logistical 
reasons and isolated at home. The symptoms settled down after 
10 days. A week prior to admission she developed severe left flank 
pain, possibly suggestive of renal calculus. A COVID antibody test 
was positive. Findings on ultrasound examination of the abdomen 
were completely normal, and a follow-up CT scan showed an area of 
wedge-like hypoattenuation within the medial interpolar aspect of 
the left kidney, with non-enhancement of the overlying renal cortex. 
The features were consistent with a renal infarct involving the medial 
interpolar aspect of the left kidney. Kidney function was normal 
(estimated glomerular filtration rate 86 mL/min) and D-dimers were 
not elevated at 448 ng/mL (normal <500 ng/mL). No other cause was 
identified for the thrombosis or systemic embolisation.
Renal infarction post COVID-19 is a rare but well-described 
complication and probably a result of a hypercoagulable state as 
described below.[10] It could potentially contribute to some cases of 
acute kidney injury described in COVID-19 infections.
Cases 8, 9 and 10: The reality of COVID-19
Case 8 was a woman in her seventies, who was admitted in Decem-
ber 2020 with moderately severe COVID-19 pneumonia. She was 
treated according to the standard protocol, which included LMWH 
and dexamethasone.
At the time of admission, the patient was in mild respiratory 
distress. Four days later she felt better, but of concern, her D-dimers 
went up to 3 786 ng/mL from 831 ng/mL 2 days previously. Her pulse 
rate was 96 bpm, her blood pressure 138/76 mmHg and her sats 92% 
on oxygen via a nasal cannula at 4 L/min. She reported pain in the 
right shoulder to the nursing staff, and 45 minutes later was found 
dead. The likely cause of death was an acute pulmonary embolus 
despite appropriate anticoagulation.
Patients with COVID-19 are at increased risk of venous 
thromboembolism, and systemic inflammation, abnormal coagu-
lation status, multiorgan dysfunction and critical illness are all 
potential contributing factors. Elevated D-dimers are an important 
predictor of risk, and the use of LMWH may be associated with 
reduced mortality in severe COVID or in patients with D-dimers >6 
times elevated.[1] In a recent meta-analysis, anticoagulation (either 
prophylactic or therapeutic), mainly with heparin, was associated 
with 50% reduced in-hospital mortality risk.[11] Both anticoagulant 
regimens reduced in-hospital all-cause mortality compared with 
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no anticoagulation, particularly in ICU cases. However, therapeutic 
anticoagulation was associated with a 2.53 times increased risk of 
bleeding, suggesting that prophylactic dosages of anticoagulant are 
probably to be preferred in non-critically ill COVID-19 patients.
Case 9 was a man in his fifties who developed COVID 19 
pneumonia while on holiday in the area. He was hospitalised in 
December 2020 with moderate to severe COVID-19 pneumonia 
confirmed on CT scan.
Although the sats were low (84% on room air and 89% on oxygen 
via  a nasal cannula at 8 L/min), the patient was not in respiratory 
distress. He was treated according to the standard protocol together 
with chest physiotherapy, and his oxygen saturation improved to 94% 
on oxygen via nasal prongs at 8 - 10 L/min. Initially he refused to use 
a rebreather mask.
Six days later the patient’s saturation dropped and settled at 88% 
on oxygen via a rebreather mask at 8 L/min. The inflammatory 
markers were still elevated. The C-reactive protein level was 268.4 
mg/mL (normal <5 mg/mL), the lactate dehydrogenase level 1 055 
ng/mL (normal <500 ng/mL) and the white cell count 18.3 × 109/L 
(normal 3.92 - 9.88 × 109/L). The D-dimer level was particularly high 
at 3 791 ng/mL. That evening, the family requested that he be moved 
to the ICU of a tertiary care hospital 250 km away to escalate the level 
of care. He was transferred by advanced life support ambulance with 
a full paramedic team and was on oxygen with cardiac monitoring 
throughout the 3-hour journey. Ten minutes before arriving at the 
hospital he had a cardiac arrest, and resuscitation was unsuccessful. 
The cause of death was not established but was probably a pulmonary 
embolus or the effects of severe hypoxaemia related to COVID-19 
pneumonia.
Case 10 was a woman in her fifties who developed COVID 19 
pneumonia in December 2020 while on holiday in the area. She was 
a longstanding insulin-dependent diabetic with hypertension. On 
admission she was severely distressed and confused with her glucose 
out of range. Sats on room air was 83%. A CT scan demonstrated 
features consistent with severe COVID-19 pneumonia, and she 
was admitted to the ICU and treated with the COVID-19 protocol 
together with remdesivir.
Her diabetes stabilised, and oxygen was given via an Airvo 2 
nasal high-flow device (Fisher & Paykel, New Zealand) and chest 
physiotherapy was commenced. Over the next few days her mental 
state improved and her sats remained between 88% and 92% on the 
Airvo 2. Non-invasive ventilation was then commenced, alternating 
with the Airvo 2. An echocardiogram was normal apart from a small 
pericardial effusion.
A repeat chest radiograph 8 days later showed no deterioration, 
and her sats stayed at ~90%. Inflammatory markers remained high, 
but she started to feel better. Four days later her electrolytes were 
normal and D-dimers only slightly elevated.
Unfortunately, in the early hours of the morning 13 days after 
admission the patient suddenly went into ventricular fibrillation. 
Attempts at resuscitation were unsuccessful. The likely cause of death 
was COVID-19 myocarditis or acute myocardial infarction.
Conclusions
A retrospective case series is presented from a small hospital in the 
Western Cape region of SA between May 20 and June 2021. Out of 
a total of ~100 admissions under the direct care of author GC, 7 
cases with unusual complications and 3 cases of sudden death are 
presented. This case series provides insights into the challenges faced 




Author contributions. GC provided the clinical information and wrote 
the initial draft. BLR provided critical review and revised the manuscript.
Funding.  None.
Conflicts of interest. None.
1. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg 
Med 2020;38(7):1504-1507. https://doi.org/10.1016/j.ajem.2020.04.048
2. Wang Y, Wang Z, Tse G, et al. Cardiac arrhythmias in patients with COVID-19. J Arrhythm 
2020;36(5):827-836. https://doi.org/10.1002/joa3.12405
3. Salman D, Vishnubala D, le Feuvre P, et al. Returning to physical activity after covid-19. BMJ 
2021;372:m4721. https://doi.org/10.1136/bmj.m4721
4. Kumar R, Kumar J, Daly C, Edroos SA. Acute pericarditis as a primary presentation of COVID-19. 
BMJ Case Rep 2020;13(8):e237617. https://doi.org/10.1136/bcr-2020-237617
5. Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-
pericarditis in COVID-19. Eur Heart J 2020;41(22):2130. https://doi.org/10.1093/eurheartj/ehaa253
6. Zantah M, Dominguez Castillo E, Townsend R, Dikengil F, Criner GJ. Pneumothorax in COVID-19 
disease – incidence and clinical characteristics. Respir Res 2020;21(1):236. https://doi.org/10.1186/
s12931-020-01504-y
7. Whittaker A, Anson M, Harky A. Neurological manifestations of COVID-19: A systematic review and 
current update. Acta Neurol Scand 2020;142(1):14-22. https://doi.org/10.1111/ane.13266
8. Maratharaj A, Thomas N, Ellul MA, et al., on behalf of the CoroNerve Study Group. Neurological and 
neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet 
Psychiatry 2020;7(10):875-882. https://doi.org/10.1016/S2215-0366(20)30287-X
9. Ahmad Alhiyari M, Ata F, Islam Alghizzawi M, Bint I Bilal A, Salih Abdulhadi A, Yousaf Z. Post 
COVID-19 fibrosis, an emerging complication of SARS-CoV-2 infection. ID Cases 2020;23:e01041. 
https://doi.org/10.1016/j.idcr.2020.e01041
10. Ammous A, Ghaffar MA, El-Charabaty E, El-Sayegh S. Renal infarction in COVID-19 patient. 
J Nephrol 2021;34(1):267-268. https://doi.org/10.1007/s40620-020-00866-2
11. Parisi R, Costanzo S, di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different 
anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: A systematic 
review and an updated meta-analysis. Semin Thromb Hemost 2021;47(4):372-391. https://doi.
org/10.1055/s-0041-1726034
Accepted 23 August 2021.
